Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts

J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):422-427. doi: 10.1007/s11596-012-0073-z. Epub 2012 Jun 9.

Abstract

This study examined the effects of combined administration of tyrosine, lecithin, L-glutamine and L-5-hydroxytryptophan (5-HTP) on heroin withdrawal syndromes and mental symptoms in detoxified heroin addicts. In the cluster-randomized placebo-controlled trial, 83 detoxified heroin addicts were recruited from a detoxification treatment center in Wuhan, China. Patients in the intervention group (n=41) were given the combined treatment with tyrosine, lecithin, L-glutamine and 5-HTP and those in the control group (n=42) were administered the placebo. The sleep status and the withdrawal symptoms were observed daily throughout the study, and the mood states were monitored pre- and post-intervention. The results showed that the insomnia and withdrawal scores were significantly improved over time in participants in the intervention group as compared with those in the control group. A greater reduction in tension-anxiety, depression-dejection, anger-hostility, fatigue-inertia and total mood disturbance, and a greater increase in their vigor-activity symptoms were found at day 6 in the intervention group than in the control group (all P<0.05). It was concluded that the neurotransmitter-precursor-supplement intervention is effective in alleviating the withdrawal and mood symptoms and it may become a supplementary method for patients' recovery from heroin addiction.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adult
  • Dietary Supplements*
  • Drug Therapy, Combination / methods
  • Female
  • Heroin Dependence / diagnosis*
  • Heroin Dependence / therapy*
  • Humans
  • Male
  • Neurotransmitter Agents / administration & dosage*
  • Placebo Effect
  • Single-Blind Method
  • Substance Withdrawal Syndrome / diagnosis
  • Substance Withdrawal Syndrome / drug therapy*
  • Substance Withdrawal Syndrome / therapy*
  • Treatment Outcome

Substances

  • Neurotransmitter Agents